Terms: = Lung cancer AND SDHA, SDH2, 6389, ENSG00000073578, FP, P31040, SDHF AND Treatment
58 results:
1. Nanoparticles targeting mutant p53 overcome chemoresistance and tumor recurrence in non-small cell lung cancer.
Bi YY; Chen Q; Yang MY; Xing L; Jiang HL
Nat Commun; 2024 Mar; 15(1):2759. PubMed ID: 38553451
[TBL] [Abstract] [Full Text] [Related]
2. Updated efficacy and safety of entrectinib in NTRK fusion-positive non-small cell lung cancer.
Cho BC; Chiu CH; Massarelli E; Buchschacher GL; Goto K; Overbeck TR; Loong HHF; Chee CE; Garrido P; Dong X; Fan Y; Lu S; Schwemmers S; Bordogna W; Zeuner H; Osborne S; John T
Lung Cancer; 2024 Feb; 188():107442. PubMed ID: 38171156
[TBL] [Abstract] [Full Text] [Related]
3. [A Case of Specific Pneumonia Diagnosed as Peritumoral Infiltration during Nivolumab treatment for Esophageal cancer].
Sasaki N; Miura A; Suzuki K; Haruki S; Yamaguchi K
Gan To Kagaku Ryoho; 2023 Apr; 50(4):526-528. PubMed ID: 37066476
[TBL] [Abstract] [Full Text] [Related]
4. ACADL suppresses PD-L1 expression to prevent cancer immune evasion by targeting Hippo/YAP signaling in lung adenocarcinoma.
Li L; Wang LL; Wang TL; Zheng FM
Med Oncol; 2023 Mar; 40(4):118. PubMed ID: 36929466
[TBL] [Abstract] [Full Text] [Related]
5. Palbociclib with Fulvestrant or Letrozole in Endocrine-Sensitive Patients with HR-Positive/HER2-Negative Advanced Breast cancer: A Detailed Safety Analysis of the Randomized PARSIFAL Trial.
Di Cosimo S; Pérez-García JM; Bellet M; Dalenc F; Gil Gil MJ; Ruiz Borrego M; Gavilá J; Sampayo-Cordero M; Aguirre E; Schmid P; Marmé F; Gligorov J; Schneeweiss A; Albanell J; Zamora P; Wheatley D; Martínez-De Dueñas E; Carañana V; Amillano K; Mina L; Malfettone A; Cortés J; Llombart-Cussac A
Oncologist; 2023 Jan; 28(1):23-32. PubMed ID: 36239405
[TBL] [Abstract] [Full Text] [Related]
6. Comparison of Efficacy and Safety of Taxanes Plus Platinum and Fluorouracil Plus Platinum in the First-Line treatment of Esophageal cancer: A Systematic Review and Meta-Analysis.
Zhao Y; Song R; Jia Y; Zhang X; Zhang S; Wu C; Zhang R; Guo Z
Curr Oncol; 2022 Sep; 29(9):6610-6627. PubMed ID: 36135088
[TBL] [Abstract] [Full Text] [Related]
7. Prognostic Evaluation of CT Imaging Big Data-Assisted Arterial Chemoembolization Combined with
Xie P; Zhang Y; He L
Comput Math Methods Med; 2022; 2022():3472982. PubMed ID: 35872936
[TBL] [Abstract] [Full Text] [Related]
8. Inhibition of Mitochondrial Biosynthesis Using a "Right-Side-Out" Membrane-Camouflaged Micelle to Facilitate the Therapeutic Effects of Shikonin on Triple-Negative Breast cancer.
Peng J; Hu X; Fan S; Zhou J; Ren S; Sun R; Chen Y; Shen X; Chen Y
Adv Healthc Mater; 2022 Sep; 11(18):e2200742. PubMed ID: 35818932
[TBL] [Abstract] [Full Text] [Related]
9. Deep Learning-based Artificial Intelligence Improves Accuracy of Error-prone lung Nodules.
Lan CC; Hsieh MS; Hsiao JK; Wu CW; Yang HH; Chen Y; Hsieh PC; Tzeng IS; Wu YK
Int J Med Sci; 2022; 19(3):490-498. PubMed ID: 35370462
[No Abstract] [Full Text] [Related]
10. Pre- and post-treatment blood-based genomic landscape of patients with ROS1 or NTRK fusion-positive solid tumours treated with entrectinib.
Dziadziuszko R; Hung T; Wang K; Choeurng V; Drilon A; Doebele RC; Barlesi F; Wu C; Dennis L; Skoletsky J; Woodhouse R; Li M; Chang CW; Simmons B; Riehl T; Wilson TR
Mol Oncol; 2022 May; 16(10):2000-2014. PubMed ID: 35338679
[TBL] [Abstract] [Full Text] [Related]
11. [A Case of Combined Modality Therapy for Progressive Esophagus cancer with Perforation Due to Preoperative Chemotherapy].
Miyoshi K; Ota Y; Sakurai T; Matsumoto M; Yamada E; Enomoto M; Iwasaki K; Nagakawa Y; Katsumata K; Tsuchida A
Gan To Kagaku Ryoho; 2022 Jan; 49(1):77-79. PubMed ID: 35046367
[TBL] [Abstract] [Full Text] [Related]
12. A comparison of two methodologies for radiotherapy treatment plan optimization and QA for clinical trials.
Geng H; Giaddui T; Cheng C; Zhong H; Ryu S; Liao Z; Yin FF; Gillin M; Mohan R; Xiao Y
J Appl Clin Med Phys; 2021 Oct; 22(10):329-337. PubMed ID: 34432946
[TBL] [Abstract] [Full Text] [Related]
13. Correlation between quantitative perfusion histogram parameters of DCE-MRI and PTEN, P-Akt and m-TOR in different pathological types of lung cancer.
Zhang B; Zhao Z; Huang Y; Mao H; Zou M; Wang C; Yu G; Zhang M
BMC Med Imaging; 2021 Apr; 21(1):73. PubMed ID: 33865336
[TBL] [Abstract] [Full Text] [Related]
14. Fast progression in non-small cell lung cancer: results from the randomized phase III OAK study evaluating second-line atezolizumab versus docetaxel.
Gandara D; Reck M; Moro-Sibilot D; Mazieres J; Gadgeel S; Morris S; Cardona A; Mendus D; Ballinger M; Rittmeyer A; Peters S
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33737340
[TBL] [Abstract] [Full Text] [Related]
15. Determining the incidence of interstitial pneumonitis and chronic kidney disease following full intensity haemopoetic stem cell transplant conditioned using a forward-planned intensity modulated total body irradiation technique.
Durie E; Nicholson E; Anthias C; Dunne EM; Potter M; Ethell M; Messiou C; Brennan J; Eagle S; Talbot J; Smyth G; Ingram W; Saran F; Mandeville HC
Radiother Oncol; 2021 May; 158():97-103. PubMed ID: 33636231
[TBL] [Abstract] [Full Text] [Related]
16. FOXF1 is required for the oncogenic properties of PAX3-FOXO1 in rhabdomyosarcoma.
Milewski D; Shukla S; Gryder BE; Pradhan A; Donovan J; Sudha P; Vallabh S; Pyros A; Xu Y; Barski A; Szabo S; Turpin B; Pressey JG; Millay DP; Khan J; Kalinichenko VV; Kalin TV
Oncogene; 2021 Mar; 40(12):2182-2199. PubMed ID: 33627785
[TBL] [Abstract] [Full Text] [Related]
17. [A Case in Which Multiple Post-Operatively Recurring Hepatocellular Carcinomas Showed a Positive Response to Sorafenib-Hepatic Arterial Infusion Chemotherapy (HAIC)Sequential Therapy].
Iwata N; Ishii Y; Yoshida Y; Kikuchi T; Mita H; Adachi Y; Adachi Y; Minami T; Ikeda K; Makiguchi Y; Hata F; Kato Y; Endo T
Gan To Kagaku Ryoho; 2021 Feb; 48(2):215-218. PubMed ID: 33597362
[TBL] [Abstract] [Full Text] [Related]
18. Platinum Nanoparticles Enhance Exosome Release in Human lung Epithelial Adenocarcinoma cancer Cells (A549): Oxidative Stress and the Ceramide Pathway are Key Players.
Gurunathan S; Kang MH; Jeyaraj M; Kim JH
Int J Nanomedicine; 2021; 16():515-538. PubMed ID: 33519199
[TBL] [Abstract] [Full Text] [Related]
19. Glucocorticoids impair type I IFN signalling and enhance rhinovirus replication.
Marcellini A; Swieboda D; Guedán A; Farrow SN; Casolari P; Contoli M; Johnston SL; Papi A; Solari R
Eur J Pharmacol; 2021 Feb; 893():173839. PubMed ID: 33359650
[TBL] [Abstract] [Full Text] [Related]
20. Symptom Burden and GOLD Classification in Medicare Advantage Patients with COPD Initiating Umeclidinium/Vilanterol or Fluticasone Propionate/Salmeterol Therapy.
Moretz C; Hahn B; White J; Goolsby Hunter A; Essoi B; Elliott C; Ray R
Int J Chron Obstruct Pulmon Dis; 2020; 15():2715-2725. PubMed ID: 33149569
[TBL] [Abstract] [Full Text] [Related]
[Next]
